arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2018-24-4-459-468arthyper-816Research ArticleЛЕКЦИЯLECTUREПрименение фиксированной комбинации лизиноприла и индапамида для оптимальной кардиопротекции у больных гипертонической болезньюThe fixed combination of lisinopril and indapamide: optimization of cardioprotection in hypertensive patientsПодзолковВ. И.PodzolkovV. I.

доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии № 2 лечебного факультета

ул. Трубецкая, д. 8–2, Москва, Россия, 119991.

MD, PhD, DSc, Professor, Head, Department of Internal Diseases # 2

8–2 Trubetskaya street, Moscow, 119991, Russia

ДрагомирецкаяН. А.DragomiretskayaN. A.

кандидат медицинских наук, доцент кафедры факультетской терапии № 2 лечебного факультета

ул. Трубецкая, д. 8–2, Москва, Россия, 119991.Тел.: +7(499)245–45–32.

PhD, Associate Professor, Department of Internal Diseases # 2

8–2 Trubetskaya street, Moscow, 119991, RussiaPhone: +7(499)245–45–32

galanina_natalia@mail.ruФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И. М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский университет)РоссияI. M. Sechenov First Moscow State Medical UniversityRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И. М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский университет)РоссияI. M. Sechenov First Moscow State Medical UniversityRussian Federation201826092018244459468Copyright © Подзолков В.И., Драгомирецкая Н.А., 20182018Подзолков В.И., Драгомирецкая Н.А.Podzolkov V.I., Dragomiretskaya N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/816

В статье представлены современные положения о про- и антигипертензивных механизмах, участвующих в формировании артериальной гипертензии, рассмотрены пути ее коррекции. Особое внимание уделено ингибитору ангиотензинпревращающего фермента лизиноприлу и тиазидоподобному диуретику индапамиду. Рассмотрены механизмы их действия и эффекты. На основании результатов многоцентровых рандомизированных клинических исследований представлены данные об антигипертензивной активности лизиноприла и индапамида и их влиянии на гипертрофию миокарда у лиц с гипертонической болезнью. Описаны потенциальные преимущества фиксированной комбинации лизиноприла и индапамида в лечении больных артериальной гипертензией.

The article presents current knowledge of рro- and antihypertensive mechanisms involved in the development of hypertension (HTN), and antihypertensive management strategies. Particular attention is paid to the angiotensin converting enzyme inhibitor lisinopril and thiazide-like diuretic indapamide. The mechanisms and effects are described. The paper discusses the results of multicenter randomized clinical trials, and the antihypertensive effects of lisinopril and indapamide and their impact on myocardial hypertrophy in hypertensive patients. The potential advantages of fixed combination of lisinopril and indapamide in the treatment of patients with HTN are also discussed.

артериальная гипертензиягипертрофия миокардафиксированная комбинациялизиноприлиндапамидhypertensionmyocardial hypertrophyfixed combinationlisinoprilindapamideСтатья опубликована при поддержке фармацевтической компании «Гедеон Рихтер» (Венгрия). The paper is supported by the company Gedeon Richter (Hungary).ReferencesVasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682–1686.Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682–1686.Федеральная служба государственной статистики. Российский статистический ежегодник. 2017 (на русском и английском языках). Здравоохранение. URL: http://www.gks.ru/free_doc/doc_2017/year/year17.pdf. Посещение 15.05.2018. [Federal State Statistics Service. Russian statistical yearbook. 2017. Health Care System. URL: http://www.gks.ru/free_doc/doc_2017/year/year17.pdf. Accessed on 15.05.2018. In Russian and English].Федеральная служба государственной статистики. Российский статистический ежегодник. 2017 (на русском и английском языках). Здравоохранение. URL: http://www.gks.ru/free_doc/doc_2017/year/year17.pdf. Посещение 15.05.2018. [Federal State Statistics Service. Russian statistical yearbook. 2017. Health Care System. URL: http://www.gks.ru/free_doc/doc_2017/year/year17.pdf. Accessed on 15.05.2018. In Russian and English].Оганов Р. Г., Масленникова Г. Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения. Кардиоваскулярная терапия и профилактика. 2012;11(1):5–10. [Oganov RG, Maslennikova GYa. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Cardiovascular Therapy and Prevention, 2012;11(1):5–10. In Russian].Оганов Р. Г., Масленникова Г. Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения. Кардиоваскулярная терапия и профилактика. 2012;11(1):5–10. [Oganov RG, Maslennikova GYa. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Cardiovascular Therapy and Prevention, 2012;11(1):5–10. In Russian].Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244–1263.Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244–1263.Morgan L, Broughton PF, Kalsheker N. Angiotensinogen: molecular biology, biochemistry and physiology. Int J Biochem Cell Biol. 1996;28(11):1211–1222.Morgan L, Broughton PF, Kalsheker N. Angiotensinogen: molecular biology, biochemistry and physiology. Int J Biochem Cell Biol. 1996;28(11):1211–1222.Ahmad S, Varagic J, Groban L, Dell’italia LJ, Nagata S, Kon ND et al. Angiotensin-(1–12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep. 2014;16(5):429. doi:10.1007/s11906-014-0429-9Ahmad S, Varagic J, Groban L, Dell’italia LJ, Nagata S, Kon ND et al. Angiotensin-(1–12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep. 2014;16(5):429. doi:10.1007/s11906-014-0429-9Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis. 2016;10(3):162–171. doi:10.1177/1753944716642677Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis. 2016;10(3):162–171. doi:10.1177/1753944716642677Robbins & Cotran Pathologic Basis of Disease, 9th Edition. Elsevier. 2014;2:639 p.Robbins & Cotran Pathologic Basis of Disease, 9th Edition. Elsevier. 2014;2:639 p.O’Rourke MF, Safar ME, Dzau V. The cardiovascular continuum extended: aging effects on the aorta and microvasculature. Vasc Med. 2010;15(6):461–468. doi:10.1177/1358863X10382946O’Rourke MF, Safar ME, Dzau V. The cardiovascular continuum extended: aging effects on the aorta and microvasculature. Vasc Med. 2010;15(6):461–468. doi:10.1177/1358863X10382946Kim SA, Park JB, O’Rourkе МF. Vasculopathy of aging and the revised cardiovascular continuum. Pulse (Basel). 2015;3(2):141–147. doi:10.1159/000435901Kim SA, Park JB, O’Rourkе МF. Vasculopathy of aging and the revised cardiovascular continuum. Pulse (Basel). 2015;3(2):141–147. doi:10.1159/000435901James PA, Oparil S, Carter BL, Cushman WC, DennisonHimmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc. 2014;311(5):507–520. doi:10.1001/jama.2013.284427James PA, Oparil S, Carter BL, Cushman WC, DennisonHimmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc. 2014;311(5):507–520. doi:10.1001/jama.2013.284427Рекомендации ВНОК по диагностике и лечению артериальной гипертензии 2013. Scardio.ru. [Guidelines for the diagnosis and treatment of arterial hypertension. Scardio.ru. 2013. In Russian].Рекомендации ВНОК по диагностике и лечению артериальной гипертензии 2013. Scardio.ru. [Guidelines for the diagnosis and treatment of arterial hypertension. Scardio.ru. 2013. In Russian].Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002; 89 (2A):3A-10A.Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002; 89 (2A):3A-10A.Hass A, Oz H, Mashavi M, Shargorodsky M. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients. J Am Soc Hypertens. 2014;8 (10):709–714. doi:10.1016/j.jash.2014.07.033Hass A, Oz H, Mashavi M, Shargorodsky M. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients. J Am Soc Hypertens. 2014;8 (10):709–714. doi:10.1016/j.jash.2014.07.033Brunner DB, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H et al. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol. 1981;11 (5):461–467.Brunner DB, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H et al. Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol. 1981;11 (5):461–467.Pharmacologic group — angiotensin converting ferments. Lisinopril. URL: https://www.rlsnet.ru/fg_index_id_192.htm (15.05.2018)Pharmacologic group — angiotensin converting ferments. Lisinopril. URL: https://www.rlsnet.ru/fg_index_id_192.htm (15.05.2018)Подзолков В. И., Тарзиманова А. И. Лизиноприл в лечении больных артериальной гипертензией. Кардиология. 2017;57(9):77–82. [Podzolkov VI, Tarzimanova AI. Lisinopril in the treatment of hypertensive patients. Kardiologiia. 2017;57(9):77–82. In Russian].Подзолков В. И., Тарзиманова А. И. Лизиноприл в лечении больных артериальной гипертензией. Кардиология. 2017;57(9):77–82. [Podzolkov VI, Tarzimanova AI. Lisinopril in the treatment of hypertensive patients. Kardiologiia. 2017;57(9):77–82. In Russian].Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin. 2005;21(1):113–119.Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin. 2005;21(1):113–119.Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD. Blood pressure and pulse pressure lowering effects, trough: peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol. 2003;42(4):491–496.Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD. Blood pressure and pulse pressure lowering effects, trough: peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol. 2003;42(4):491–496.Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997;95(6):1464–70.Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997;95(6):1464–70.Rosei EA, Rizzoni D, Comini S, Boari G; NebivololLisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl. 2003;1:30–5.Rosei EA, Rizzoni D, Comini S, Boari G; NebivololLisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl. 2003;1:30–5.Jensen HA. Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. Clin Exp Hypertens A. 1992;14(6):1095–110.Jensen HA. Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. Clin Exp Hypertens A. 1992;14(6):1095–110.Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Lisinopril or nifedipine in essential hypertension? A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens. 1991;9(12):1097–104.Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Lisinopril or nifedipine in essential hypertension? A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens. 1991;9(12):1097–104.Diamant M, Vincent HH. Lisinopril versus enalapril: evaluation of trough: peak ratio by ambulatory blood ssure monitoring. J Hum Hypertens. 1999;13(6):405–412.Diamant M, Vincent HH. Lisinopril versus enalapril: evaluation of trough: peak ratio by ambulatory blood ssure monitoring. J Hum Hypertens. 1999;13(6):405–412.Landmark K, Tellnes G, Fagerthun HE, Larsen S. Treatment of hypertension with the ACE inhibitor lisinopril. A multicenter study of patients with mild to moderate hypertension in general practice. Tidsskr Nor Laegeforen. 1991;111(26):3176–3179.Landmark K, Tellnes G, Fagerthun HE, Larsen S. Treatment of hypertension with the ACE inhibitor lisinopril. A multicenter study of patients with mild to moderate hypertension in general practice. Tidsskr Nor Laegeforen. 1991;111(26):3176–3179.Pharmacologic group — diuretics. URL: https://www.rlsnet.ru/tn_index_id_36025.htm (15.05.2018)Pharmacologic group — diuretics. URL: https://www.rlsnet.ru/tn_index_id_36025.htm (15.05.2018)Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014;19(1):5–13. doi:10.1177/1074248413497257Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther. 2014;19(1):5–13. doi:10.1177/1074248413497257DiNicolantonio JJ, Bhutani J, Lavie CJ, O’Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Future Cardiol. 2015;11(2):203–217. doi:10.2217/fca.14.83DiNicolantonio JJ, Bhutani J, Lavie CJ, O’Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Future Cardiol. 2015;11(2):203–217. doi:10.2217/fca.14.83Roush GC, Abdelfattah R, Song S, Kostis JB, Ernst ME, Sica DA. Hydrochlorothiazide and alternative diuretics versus reninangiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. J Hypertens. 2018;36(6):1247–1255.Roush GC, Abdelfattah R, Song S, Kostis JB, Ernst ME, Sica DA. Hydrochlorothiazide and alternative diuretics versus reninangiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. J Hypertens. 2018;36(6):1247–1255.Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig. 2007;27 (11):735–53.Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig. 2007;27 (11):735–53.Напалков Д. А. Антигипертензивная эффективность современного метаболически нейтрального диуретика индапамида. Лечащий врач. 2007;8:69–70. [Napalkov DA. Antihypertensive efficacy of modern metabolic neutral diuretic indapamide. Lechaschij Vrach = Treating Physician. 2007;8:69–70. In Russian].Напалков Д. А. Антигипертензивная эффективность современного метаболически нейтрального диуретика индапамида. Лечащий врач. 2007;8:69–70. [Napalkov DA. Antihypertensive efficacy of modern metabolic neutral diuretic indapamide. Lechaschij Vrach = Treating Physician. 2007;8:69–70. In Russian].Инструкция по медицинскому применению препарата Диротон® Плюс. URL: vidal.ru›drugs/diroton-plus. [Manual for the medication Diroton®Plus. URL: vidal.ru›drugs/diroton-plus].Инструкция по медицинскому применению препарата Диротон® Плюс. URL: vidal.ru›drugs/diroton-plus. [Manual for the medication Diroton®Plus. URL: vidal.ru›drugs/diroton-plus].Kaplan NM. Indapamide: is it the better diuretic for hypertension? Hypertension. 2015;65(5):983–984. doi:10.1161/HYPERTENSIONAHA.115.05138Kaplan NM. Indapamide: is it the better diuretic for hypertension? Hypertension. 2015;65(5):983–984. doi:10.1161/HYPERTENSIONAHA.115.05138Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65 (5):1033–1040. doi:10.1161/HYPERTENSIONAHA.114.05122Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65 (5):1033–1040. doi:10.1161/HYPERTENSIONAHA.114.05122Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a metaanalysis. J Cell Mol Med. 2017;21(11):2634–2642. doi:10.1111/jcmm.13205Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a metaanalysis. J Cell Mol Med. 2017;21(11):2634–2642. doi:10.1111/jcmm.13205Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like eiuretics: a meta-analysis. Am J Hypertens. 2015;28(12):1453–1463. doi:10.1093/ajh/hpv050Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like eiuretics: a meta-analysis. Am J Hypertens. 2015;28(12):1453–1463. doi:10.1093/ajh/hpv050Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19(2):303–309.Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19(2):303–309.Gosse P, Sheridan DJ, Zannad F, Dubourg O, Guéret P, Karpov Y et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18(10):1465–75.Gosse P, Sheridan DJ, Zannad F, Dubourg O, Guéret P, Karpov Y et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18(10):1465–75.Senior R, Imbs JL, Bory M, Amabile G, Denis B, Zannad F et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol. 1993;22 Suppl 6: S106–110.Senior R, Imbs JL, Bory M, Amabile G, Denis B, Zannad F et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol. 1993;22 Suppl 6: S106–110.Подзолков В. И., Брагина А. Е. Стратегия использования индапамида ретард в профилактике синдрома раннего старения сосудов. Кардиология. 2015;55 (11):106–112. [Podzolkov VI, Bragina AE. The strategy of indapamide retard use in the prevention of the early vascular aging syndrome. Kardiologiia. 2015;55 (11):106–112. In Russian].Подзолков В. И., Брагина А. Е. Стратегия использования индапамида ретард в профилактике синдрома раннего старения сосудов. Кардиология. 2015;55 (11):106–112. [Podzolkov VI, Bragina AE. The strategy of indapamide retard use in the prevention of the early vascular aging syndrome. Kardiologiia. 2015;55 (11):106–112. In Russian].ALLHAT Authors. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker VS diuretic. J Am Med Assoc. 2002;288 (23):2981–2996.ALLHAT Authors. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker VS diuretic. J Am Med Assoc. 2002;288 (23):2981–2996.Parving HH. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications. 1996;10 (3):133–135.Parving HH. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications. 1996;10 (3):133–135.Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan And Lisinopril Microalbuminuria (CALM) study. Br Med J. 2000;321(7274):1440–1444.Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan And Lisinopril Microalbuminuria (CALM) study. Br Med J. 2000;321(7274):1440–1444.Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W et al; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–1903. doi:10.1056/NEJMoa1303154Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W et al; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–1903. doi:10.1056/NEJMoa1303154Ruggenenti P. Dual renin-angiotensin system blockade for nephroprotection. Nephrol Ther. 2017;13 Suppl 1: S43–S45. doi:10.1016/j.nephro.2017.02.006Ruggenenti P. Dual renin-angiotensin system blockade for nephroprotection. Nephrol Ther. 2017;13 Suppl 1: S43–S45. doi:10.1016/j.nephro.2017.02.006Джаиани Н. А. Выбор лизиноприла для терапии артериальной гипертонии у пациентов с сопутствующей патологией. Рациональная фармакотерапия в кардиологии. 2014;10 (5):565–571. [Dzhaiani NA. Choice of Lisinopril for treatment of hypertension in patients with concomitant diseases. Ration Pharmacother Cardiol. 2014;10(5):565–571. In Russian].Джаиани Н. А. Выбор лизиноприла для терапии артериальной гипертонии у пациентов с сопутствующей патологией. Рациональная фармакотерапия в кардиологии. 2014;10 (5):565–571. [Dzhaiani NA. Choice of Lisinopril for treatment of hypertension in patients with concomitant diseases. Ration Pharmacother Cardiol. 2014;10(5):565–571. In Russian].Поздняков Ю. М., Волков В. С., Милягин В. А, Якушин С. С. Монотерапия артериальной гипертонии I–II степени. Опыт применения лизиноприла (результаты многоцентрового исследования). Болезни сердца и сосудов. 2006;1(4):47–50. [Pozdnjakov YM, Volkov VS, Milyagin VA, Jakushin SS. Monotherapy hypertension grade I–II. Experience of using Lisinopril (results of a multicenter study). Bolezni Serdtsa I Sosudov = Cardiovascular Disease. 2006;1(4):47–50. In Russian].Поздняков Ю. М., Волков В. С., Милягин В. А, Якушин С. С. Монотерапия артериальной гипертонии I–II степени. Опыт применения лизиноприла (результаты многоцентрового исследования). Болезни сердца и сосудов. 2006;1(4):47–50. [Pozdnjakov YM, Volkov VS, Milyagin VA, Jakushin SS. Monotherapy hypertension grade I–II. Experience of using Lisinopril (results of a multicenter study). Bolezni Serdtsa I Sosudov = Cardiovascular Disease. 2006;1(4):47–50. In Russian].Чазова И. Е., Ратова Л. Г. Ирузид и Ирумед. Нефропротекция в лечении больных артериальной гипертонией. Consilium Medicum. 2005;7(1):3–7. [Chazova EI, Ratova LG. Iruzid and Irumed. Nephroprotection in patients with essential hypertension. Consilium Medicum. 2005;7(1):3–7. In Russian].Чазова И. Е., Ратова Л. Г. Ирузид и Ирумед. Нефропротекция в лечении больных артериальной гипертонией. Consilium Medicum. 2005;7(1):3–7. [Chazova EI, Ratova LG. Iruzid and Irumed. Nephroprotection in patients with essential hypertension. Consilium Medicum. 2005;7(1):3–7. In Russian].Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;122(3):290–300.Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;122(3):290–300.

The authors declare that there are no conflicts of interest present.